Biomimetic functional and regenerative cartilage implant
US10765521B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Oct 19, 2017 |
| Grant date | Sep 8, 2020 |
| Priority date | — |
| Expiry date | Oct 19, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L27/58
- WIPO fieldMedical technology
- WIPO sectorInstruments
Abstract
An artificial cartilage is provided whereby a fixed negative charged hydrogel has been infused within a restrictive swelling network, which limits and restricts the thickness of the artificial cartilage. At least 60% of the volume of the artificial cartilage is composed of the restricted and swollen hydrogel. The restrictive swelling network restricts the hydrogel to swell not more than 10% with respect to its maximum swelling capacity, i.e. a swelling capacity to swell 10-fold more is retained. The hydrogel within the restrictive swelling network has an equilibrium stiffness between 0.5 and 2 MPa to resist external loads applied to the top surface layer or the bottom surface layer of the artificial cartilage. The hydrogel has a fixed negative charge density of −0.17 to −0.23 mEg/ml and is capable of swelling between 2-15 times compared to the volume of the hydrogel without being restricted.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.